Fear is contagious. You can see it playing out these days in the drug industry. When Merck
Just months after that debacle, another epidemic of fear is spreading in the drug sector. The industry was stunned when BiogenIDEC
Now it looks as if the agency is taking no chances. GlaxoSmithKline
Unfortunately for drug industry investors, until BiogenIDEC, Elan, and the FDA determine the nature of Tysabri's problem, Glaxo's research efforts are likely to be frozen. And Glaxo probably won't be the only company affected --Schering-Plough
For more on the pharmaceutical industry's woes, see:
Fool contributor Brian Gorman is a freelance writer in Chicago. He does not own shares of any companies mentioned in this article.